{
  "data": {
    "indicator": {
      "slug": "cumulative-drug-approval-applications-under-priority-review",
      "name": "Cumulative drug approval applications under priority review",
      "definition": "Total cumulative number of drug approval applications granted priority review status since program inception.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "points": [
      {
        "period_start": "2020-01-01",
        "period_label": "end of 2024",
        "value": 496,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX",
        "url": "https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX",
        "source_org": "State Council",
        "source": {
          "org": "State Council of China",
          "org_short_name": "State Council",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "CN"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}